Galmed Pharmaceuticals Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLMD research report →
About the company
Galmed Pharmaceuticals Ltd. , a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
- CEO
- Allen Baharaff
- IPO
- 2014
- Employees
- 5
- HQ
- Ramat Gan, IL
Price Chart
- Market Cap
- $3.13M
- P/E
- -0.24
- P/S
- 0.00
- P/B
- 0.24
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.04%
- ROIC
- -53.92%
- Revenue
- $0 · 0.00%
- Net Income
- $-10,309,000 · -37.14%
- EPS
- $-2.39 · 70.42%
- Op Income
- $-8,510,000
- FCF YoY
- -7.40%
- 52W High
- $2.34
- 52W Low
- $0.41
- 50D MA
- $0.61
- 200D MA
- $0.86
- Beta
- 0.74
- Avg Volume
- 3.48M
Get TickerSpark's AI analysis on GLMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GLMD coverage
Recent articles, reports, and earnings notes.
No research on GLMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLMD report →Similar companies
Peers in the same neighborhood.